| Name | Title | Contact Details |
|---|---|---|
Gabriella Silva |
CFO Rotational Financial Analyst | Profile |
Rob Bucenell |
Executive Director, Human Resources | Profile |
Jed Brown |
Senior Director, Clinical Supply Chain Management | Profile |
Lesa Whitehead |
Talent Acquisition | Profile |
Francisca Ekukole |
Director, Human Resources | Profile |
Family Service offers a variety of programs and services focused on increasing opportunities for adults, protecting seniors, reducing substance abuse, improving the lives of those with mental illness, preparing children and adolescents for the future, ...
Veritas Pharma Inc (trading symbol CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP) is an early stage pharmaceutical company developing innovative cannabinoid prescription medicines to treat medical conditions such as pain, emesis (nausea/vomiting), glaucoma, and epilepsy. Using a ‘lean and mean’ approach to product development, the company aims to select candidate medicines using classical pharmacology techniques and then immediately evaluate them in the clinic to maximize both product value and shareholder return. Veritas’s scientists are an inter-disciplinary team that consists of chemists, pharmacologists, anesthetists, and clinical pharmacologists. Their focus is to use their knowledge to streamline the development of cannabis based treatments to capture considerable market share. Also through its wholly owned subsidiary, Sechelt Organic Marijuana Corp., has applied to Health Canada for a medical marijuana production and distribution license under the Marihuana for Medical Purposes Regulations (the “MMPR“).
Althera Pharmaceuticals, a company focused on heart health, announces FDA approval of Roszet (rosuvastatin and ezetimibe) tablets. Founded in 2010, Althera develops innovative patient focused medicines to improve cardiovascular health.
Lucentis is a South San Francisco, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Accord Healthcare is a global provider of generic and specialty pharmaceuticals. Our focus on a rapidly expanding portfolio of affordable generic…